Abstract
Retroviral vectors are the frequently applied gene delivery vehicles for clinical gene therapy, but specificity of the immunogenicity to the protein encoded by the inserted gene of interest is a problem which needs to be overcome. Here, we describe human cytotoxic T-lymphocyte (CTL) clones recognizing epitopes derived from the protein encoded by the retroviral vector backbone, which were established during the course of our attempts to generate CTLs against cytomegalovirus (CMV) or human papilloma virus (HPV) in vitro. In the case of healthy CMV-seronegative donors, CTL lines specific for retrovirally transduced cells were generated in four out of eight donors by stimulating CD8 T cells with CD40-activated B (CD40-B) cells retrovirally transduced with CMV-pp65. Two CTL clones derived from one of the CTL lines were found to recognize epitopes from gag in the context of HLA-B*4403 and -B*4601, respectively. Similarly, an HLA-B*3501-restricted CTL clone from a cervical cancer patient recognized an epitope located in the junctional regions of the gag and pol sequences. These results show that polypeptides encoded by components of the retroviral vector backbone are in fact immunogenic, generating CTLs in vitro in human cells. Thus, potential CTL responses to retroviral products should also be considered in clinical settings.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hacein-Bey-Abina S et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185–1193.
Tait DL et al. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin Cancer Res 1999; 5: 1708–1714.
Song ES et al. Antigen presentation in retroviral vector-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1997; 94: 1943–1948.
Podevin G et al. In-vivo retroviral gene transfer to the liver is cancelled by an immune response against the corrected cells. Can it be avoided? Pediatr Surg Int 2002; 18: 595–599.
McCormack JE et al. Anti-vector immunoglobulin induced by retroviral vectors. Hum Gene Ther 1997; 8: 1263–1273.
Lutzko C et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood 1999; 93: 1895–1905.
Kang E et al. In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. Hum Gene Ther 2001; 12: 1663–1672.
Izembart A et al. In vivo retrovirus-mediated gene transfer to the liver of dogs results in transient expression and induction of a cytotoxic immune response. Hum Gene Ther 1999; 10: 2917–2925.
Baum C et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099–2114.
Aubert D et al. Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat. Mol Ther 2002; 5: 388–396.
Kim SH et al. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 1998; 72: 994–1004.
Hildinger M, Abel KL, Ostertag W, Baum C . Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 73: 4083–4089.
Riviere I, Brose K, Mulligan RC . Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733–6737.
Yu SS, Kim JM, Kim S . High efficiency retroviral vectors that contain no viral coding sequences. Gene Therapy 2000; 7: 797–804.
Walker RE et al. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat Med 1998; 4: 852–856.
Bonini C et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–1724.
Riddell SR et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216–223.
Kinsella TM, Nolan GP . Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405–1413.
Byun J et al. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy. Gene Therapy 1996; 3: 780–788.
Krall WJ et al. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Therapy 1996; 3: 37–48.
Kondo E et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002; 169: 2164–2171.
Kondo E et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood 2004; 103: 630–638.
Parker KC, Bednarek MA, Coligan JE . Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163–175.
Barber LD et al. The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. J Exp Med 1996; 184: 735–740.
Chen W, Qin H, Chesebro B, Cheever MA . Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL- 3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol 1996; 70: 7773–7782.
Long Z et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther 1998; 9: 1165–1172.
Heim DA et al. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol Ther 2000; 1: 533–544.
Wekerle T, Sykes M . Mixed chimerism and transplantation tolerance. Annu Rev Med 2001; 52: 353–370.
Gross DA et al. CD4+CD25+ regulatory T cells inhibit immune-mediated transgene rejection. Blood 2003; 102: 4326–4328.
Zhao Y, Low W, Collins MK . Improved safety and titre of murine leukaemia virus (MLV)-based retroviral vectors. Gene Therapy 2000; 7: 300–305.
Akatsuka Y et al. Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines. Tissue Antigens 2002; 59: 502–511.
Schultze JL et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100: 2757–2765.
von Bergwelt-Baildon MS et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002; 99: 3319–3325.
Schultze JL et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995; 92: 8200–8204.
Horn PA et al. Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood 2002; 100: 3960–3967.
Acknowledgements
NIH-3T3-hCD40 ligand cells were kindly provided by Dr Gordon Freeman. Valuable discussions and suggestions by Drs T Kiyono, A Uenaka, Y Nagata, M Yazaki, T Tsurumi and E Nakayama are highly appreciated. We are very grateful to Y Matsudaira, K Nishida, Y Nakao and H Tamaki for their expert technical assistance. This study was supported by a Grant-in-Aid for Scientific Research (YA, YM) and a Grant-in-Aid for Scientific Research on Priority Areas (TT) from the Ministry of Education, Culture, Science, Sports, and Technology, Japan; Research on Human Genome, Tissue Engineering Food Biotechnology (YA, YK, YM, TT) and Second Term Comprehensive 10-year Strategy for Cancer Control (TT), from the Ministry of Health, Labour, and Welfare, Japan; a special project grant from Aichi Cancer Center; Nagono Medical Research Grant (KK, YA); and a grant from Aichi Cancer Research Foundation (YA).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kondo, E., Akatsuka, Y., Nawa, A. et al. Retroviral vector backbone immunogenicity: identification of cytotoxic T-cell epitopes in retroviral vector-packaging sequences. Gene Ther 12, 252–258 (2005). https://doi.org/10.1038/sj.gt.3302406
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302406